Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Recurrent Glioblastoma
NCT06598787Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in glioblastoma (GBM), sponsored by Biokin Pharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06598787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598787.